Distinguished in Prostate Cancer

Dr. Randy F. Sweis

Hematology Oncology | Hematology | Oncology
The University Of Chicago
5841 S Maryland Ave, 
Chicago, IL 
Accepting New Patients
Offers Telehealth
Distinguished in Prostate Cancer
The University Of Chicago
5841 S Maryland Ave, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Randy Sweis is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Sweis is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Bladder Cancer, WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, and Chromophobe Renal Cell Carcinoma. Dr. Sweis is currently accepting new patients.

His clinical research consists of co-authoring 63 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Prostate Cancer.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
The University Of Chicago Medical Center
Uchicago Medicine Northwest Indiana
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

THE UNIVERSITY OF CHICAGO
5841 S Maryland Ave, Chicago, IL 60637
Other Locations
OHIOHEALTH CORPORATION
5141 W Broad St, Suite 130, Columbus, OH 43228

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of SRK-181 Alone and in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of SRK-181 Alone and in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
Enrollment Status: Completed
Publish Date: April 29, 2025
Intervention Type: Biological
Study Drugs: SRK-181, Anti-PD-(L)1 Antibody Therapy
Study Phase: Phase 1
A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive Cancer
A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive Cancer
Enrollment Status: Withdrawn
Publish Date: October 18, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Procedure, Other, Biological, Drug
Study Drugs: Atezolizumab, Glycosylated Recombinant IL-7
Study Phase: Phase 2
A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or Lymphomas
A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Enrollment Status: Terminated
Publish Date: December 30, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 1
View 4 Less Clinical Trials

63 Total Publications

The current and future role of systemic therapy in non-muscle-invasive bladder cancer.
The current and future role of systemic therapy in non-muscle-invasive bladder cancer.
Journal: Cancer
Published: February 18, 2025
Similar Doctors
Elite in Prostate Cancer
Dr. Russell Z. Szmulewitz
Hematology Oncology | Hematology | Oncology
Elite in Prostate Cancer
Dr. Russell Z. Szmulewitz
Hematology Oncology | Hematology | Oncology

The University Of Chicago

1101 S Canal St, Suite 201, 
Chicago, IL 
 (5.7 miles away)
877-336-5667
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Russell Szmulewitz is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Szmulewitz is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Orchiectomy. Dr. Szmulewitz is currently accepting new patients.

David Vanderweele
Elite in Prostate Cancer
Dr. David Vanderweele
Hematology | Oncology
Elite in Prostate Cancer
Dr. David Vanderweele
Hematology | Oncology
675 N St Clair St Ste 20-150, Galter Pavilion, 
Chicago, IL 
 (7.4 miles away)
866-587-4322
Experience:
19+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Vanderweele is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Vanderweele has been practicing medicine for over 19 years and is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Non-Muscle Invasive Bladder Cancer, Orchiectomy, and Prostatectomy.

Edward M. Schaeffer
Elite in Prostate Cancer
Dr. Edward M. Schaeffer
Oncology
Elite in Prostate Cancer
Dr. Edward M. Schaeffer
Oncology
675 N St Clair St Ste 20-150, Galter Pavilion, 
Chicago, IL 
 (7.4 miles away)
312-695-8146
Experience:
25+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Edward Schaeffer is an Oncologist in Chicago, Illinois. Dr. Schaeffer has been practicing medicine for over 25 years and is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Bladder Cancer, Prostatectomy, and Ureteroscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sweis's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 7 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile